Hopp til innhold

Get alerts of updates about «Who will get the coronavirus vaccine?»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Who will get the coronavirus vaccine?

Article

Who will get the coronavirus vaccine?

Here you will find information about which groups are offered coronavirus vaccine and when we expect that the various groups will have received an offer.

Film1_Mangfold.png

Here you will find information about which groups are offered coronavirus vaccine and when we expect that the various groups will have received an offer.


These will be offered a coronavirus vaccine: 

Risk groups

By risk groups we mean people with an increased risk of a severe COVID-19 disease course. These include:

  • Residents in nursing homes

  • Everyone who is 65 years or older

  • People aged 5–64 years with one or more defined diseases / conditions that increase the risk of a severe disease course and death from COVID-19. See the section below for specification of different diseases / conditions and age groups.

Other groups

  • Healthcare personnel and other employees in the health and care service.

  • Everyone over 16 years.

  • Children 5-15 years can also be vaccinated if they and their parents wish.

Risk groups

People with the following disease/ conditions are defined as medical risk groups: 

  • Organ transplant*
  • Immunodeficiency*
  • Hematologic (blood) cancer in the last 5 years*
  • Other active cancer, ongoing or recently finished treatment for cancer (especially immunosuppressive therapy, radiation therapy to the lungs or chemotherapy)* 
  • Neurological or muscular disease with impaired coughing strength or lung function (e.g., ALS and cerebral palsy)*
  • Downs Syndrome*
  • Chronic kidney disease or significantly impaired renal function
  • Chronic liver disease or significantly impaired liver function 
  • Immunosuppressive therapy, e.g. with autoimmune diseases
  • Diabetes  
  • Chronic lung disease, including severe asthma that has required the use of high-dose inhaled steroids or steroid tablets during the last year
  • Obesity with body mass index (BMI) of ≥ 35 kg/m2 or higher
  • Dementia 
  • Chronic cardiovascular disease (except high blood pressure)
  • Stroke

Other serious and / or chronic diseases may also increase the risk of a severe disease course.

* These diseases/ conditions can give a high risk for a severe disease course and death among younger people. 

For more detailed information about diseases/conditions that can give an increased risk for a severe COVID-19 disease course see: 

Getting the vaccine

The solutions used for appointments vary between municipalities. In some places, drop-in vaccination is available without the need for an appointment. Check your municipality's website for information about the local arrangements.

The vaccine is free.

People who belong to these groups and are resident or staying temporarily in Norway can have the vaccine as part of the immunisation programme. 

Rationale for the recommendations to the different groups

  • Everyone from 16 years and above are recommended (should) to be given a primary vaccination series. This is primarily based on the risk of a severe COVID-19 disease course. It is the oldest, and people with certain diseases and conditions who have the greatest risk of a severe disease course and death from COVID-19 disease. Although most young and healthy people recover well from COVID-19, some in this group may also become seriously ill. In addition to protecting those who are vaccinated, vaccination will also help to reduce transmission in society.

  • Children aged 5-15 years with severe underlying diseases should be given the primary vaccination series for the coronavirus vaccine. Even though the overall risk for severe COVID-19 disease for them is low, this group is particularly vulnerable and should therefore be vaccinated.
  • Everyone from the age of 45 and up, and younger people who belong to the risk groups are recommended (should) also take a booster dose when 20 weeks have passed since dose 2. This is also mainly to reduce the risk of severe COVID-19 disease  in these groups.

  • People 18-45 years who do not belong to the risk groups are offered (can take) a booster dose of COVID-19 vaccine. Although most young and healthy people cope with COVID-19 well, there are also some in this group who can become seriously ill. Booster vaccines are not approved under 18 years of age.

  • In addition to protecting those who are vaccinated, vaccination has also made a significant contribution to reducing transmission in society. This effect on ttransmission now appears to be smaller for the omicron variant, while the effect against severe disease course is still good.

  • Children 5-15 years: Are offered (can take) one or two doses of coronavirus vaccine if they and their parents wish. The Norwegian Institute of Public Health has assessed that vaccination of children aged 5-15 can have be beneficial, but the benefit is limited since the risk of severe disease course is already very low. Children and adolescents will also be able to receive broad and lasting protection by having COVID-19. The Norwegian Institute of Public Health nevertheless believes that it is appropriate for children in this age group to be offered a vaccine for those who want it. The offer is most relevant for children with chronic diseases, children in contact with vulnerable people, and children who will stay or move to countries with a high risk of infection or poorer access to health services.

  • Read more about recommendations:

For further information about booster doses see: 

Pregnancy and breastfeeding

After recovery from COVID-19

History

24.01.2022: New paragraph about children 5-15 years added under "rationale".

14.01.2022: Updated text in line with expanded vaccine offer for children announced today. The section on protection and immunity after vaccination has been adjusted with updated information on the effect of the vaccines against the omicron variant.

12.01.2022: Replaced "full vaccination" with "primary vaccination series" to avoid confusion with booster doses.

20.12.2021: New text about 5-11 year olds. Link to booster doses.

03.12.2021: Updated rationale

10.11.2021: Updated section about the rationale for the vaccine - booster doses, third doses and pregnancy

04.09.2021: Added text about the offer of coronavirus vaccine for adolescents 12-15 years. Removed text about priority groups, since there is now good access to vaccine. Otherwise some minor adjustments and text editing that do not entail any change in existing advice and recommendations.

18.08.2021: Updated with information regarding vaccination of 16-17-year-olds

29.07.2021: Adolescents 12-17 years - removed sentence: These can then be offered the BioNTech and Pfizer vaccine, which is approved for use from the age of 12 years.

02.07.2021: Removed paragraph about pregnancy and breastfeeding and added link to a page with further advice

02.07.2021: Young and healthy people will also benefit from the vaccine. Although most people cope well with COVID-19, there are some in this group who could also become seriously ill.

22.06.2021: Added sentence about 2003 cohort being offered the vaccine from BioNTech/Pfizer

04.06.2021: Changed ages from 16-17 years til 12-17 years

02.06.2021: Updated paragraph about vaccination of children.

02.06.2021: Updated link to vaccination of health care workers

27.05.2021: Added sentences about lower age groups and people with problematic substance abuse

21.05.2021: Added groups 10 and 11

20.05.2021: Removed "It has not yet been decided how the coronavirus vaccine will be offered to healthy people aged 18-44."

05.05.2021: Removed sentence "as long as they feel well and do not have lasting effects from the disease at the time of vaccination"

03.05.2021: Under the list of risk groups, Down's syndrome has been highlighted as a separate priority group.

29.04.2021: Changed advice about vaccination of pregnant women so that it can be considered if the benefits outweigh the disadvantages. Breastfeeding women can be vaccinated.

19.03.2021: Removed cystic fibrosis as example under chronic lung diseases

12.03.2021: Added vaccination scenario in English

10.03.2021: Added cerebral palsy to list of neurological or musculoskeletal diseases. Updated section about recovery from COVID-19

09.03.2021: Added sentence about age cohorts, that everyone born in the same year will be vaccinated at the same time.

01.03.2021: Updates to section about prioritisation of healthcare personnel.

18.02.2021: Ungdom 16-18 - added referral to risk group list. Updated priority list - updated paragraph about prioritisation of healthcare personnel.

15.02.2021: Added sentence: "It has not yet been decided how the coronavirus vaccine will be offered to healthy people aged 18-44 years outside the prioritised groups."

04.02.2021: Removed paragraph about children in risk groups. Emphasised that two groups (65-74 years and people 18-64 years with condition marked with *) in point 4 shall be offered the vaccine at the same time. New text about 16-17 year-olds with severe and complex diseases and congenital syndromes with high risk can be considered for vaccination. Link to risk groups.

08.01.2021: New setup with one priority list for COVID-19 vaccination and one for medical risk groups. New definition of asthma: severe asthma that has resulted in the use of high-dose inhaled steroids or steroid tablets in the past year. New link to risk groups. Updated advice for pregnant and breastfeeding women.

05.01.2021: added sentence about people who are resident in Norway being taking the vaccine.

04.01.2021: added "selected groups of healthcare personnel to order of priority"

31.12.2020: Added section about vaccination after recovery from COVID-19